RECURSION PHARMACEUTICALS, INC.
Recursion Pharmaceuticals (RXRX) reported Q2 GAAP results with a net loss of $131.005 million, or -$0.25 per share, compared with a $171.897 million loss, or -$0.41 per share, a year earlier. Revenue fell 42.0% to $7.670 million from $13.223 million.
Recursion Pharmaceuticals (Nasdaq: RXRX) reported second-quarter results for the period ended June 30, 2026 and provided pipeline updates. Genentech exercised an option to advance the collaboration’s first neuroscience target into an early discovery program. Recursion cut 2026 cash operating expense guidance to under $375 million. It also updated REC-4881 Phase 2 plans and said REC-7735 Phase 1/2 starts in 2H26.
RECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q0226.htm EX-99.1 Document Exhibit 99.1 Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program • Genentech advanced the collaboration's first neuroscience target into a joint early discover
Over the past 7 days, alphai's AI scored 4 news stories mentioning RXRX (RECURSION PHARMACEUTICALS, INC.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 1 bearish.
Recent RXRX coverage spans insider activity, earnings and technology.
In the last 30 days, RXRX insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($98K). The most active reporter was Borgeson Blake with 1 filing. 100% of activity was filed under pre-arranged Rule 10b5-1 plans.
Widening losses and sharp revenue decline increase near-term funding and execution risk, likely pressuring sentiment.
New Genentech option exercise and pipeline execution update should support RXRX sentiment, with focus on platform validation and near-term cash guidance.
Near-term sentiment likely positive on platform validation and pipeline momentum, with guidance reduction supporting downside risk control.
Milestone-triggered option exercise supports near-term cash inflow and validates Recursion’s AI target-discovery workflow with Genentech.
This is a high-risk, long-duration biotech bet; the article emphasizes ongoing losses and limited trailing revenue, implying catalyst dependence.
alphai scores every news story that mentions RXRX with an AI model for sentiment and relevance, and aggregates insider trades from RECURSION PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Recursion Pharmaceuticals (RXRX) reported Q2 GAAP results with a net loss of $131.005 million, or -$0.25 per share, compared with a $171.897 million loss, or -$0.41 per share, a year earlier. Revenue fell 42.0% to $7.670 million from $13.223 million.
1 min readRecursion Pharmaceuticals (Nasdaq: RXRX) reported second-quarter results for the period ended June 30, 2026 and provided pipeline updates. Genentech exercised an option to advance the collaboration’s first neuroscience target into an early discovery program. Recursion cut 2026 cash operating expense guidance to under $375 million. It also updated REC-4881 Phase 2 plans and said REC-7735 Phase 1/2 starts in 2H26.
6 min readRECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q0226.htm EX-99.1 Document Exhibit 99.1 Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program • Genentech advanced the collaboration's first neuroscience target into a joint early discover
6 min readRecursion said Genentech (Roche) exercised the first validated target option from a 4.5-year AI drug discovery collaboration. Acceptance triggers a $3 million milestone to Recursion, bringing total cash paid since 2021 to $216 million. Recursion can earn up to $300 million per program plus royalties. The target and indications are undisclosed.
6 min readArk Invest founder Cathie Wood bought Tesla (TSLA), SoFi Technologies (SOFI), and Recursion Pharmaceuticals (RXRX) across ARK ETFs. Tesla deliveries rose 25% YoY to 480,126 vehicles; shares fell ~7.5% after Q2 results. SoFi added members and reported 41% adjusted revenue growth. Recursion is a clinical-stage AI drug developer with $66M trailing revenue.
5 min readRecursion is developing REC-4539, a cancer drug candidate targeting LSD1 in small-cell lung cancer and AML, using AI to design an improved version of an existing target. The program is early, with safety and efficacy data expected in the second half of 2027. Recursion cut Q1 cash operating expenses 30% YoY, ended with $665M cash, and expects under $390M for 2024; partnerships with Sanofi and Roche contributed $500M+ in inflows and 10 milestones. Analysts’ average target is $6.64.
4 min readRECURSION PHARMACEUTICALS, INC. (RXRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. rxrx-20260617 0001601830 FALSE 0001601830 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
3 min readGibson Christopher sold 40,000 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.62 ($0.14M total) on 2026-06-05 under a Rule 10b5-1 trading plan.
2 min readKhan Najat (CEO and President) sold 23,588 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.58 on 2026-06-05 under a Rule 10b5-1 trading plan.
2 min readBumpus Namandje sold 4,386 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.54 on 2026-06-03 under a Rule 10b5-1 trading plan.
2 min read
